The antiallergic mast cell stabilizers lodoxamide and bufrolin as the first high and equipotent agonists of human and rat GPR35

Molecular Pharmacology

Volumn 85, Issue 1, 2014, Pages 91-104

  MacKenzie, Amanda E ^a   Caltabiano, Gianluigi ^a,c,d   Kent, Toby C ^e   Jenkins, Laura ^a   McCallum, Jennifer E ^a,b   Hudson, Brian D ^a   Nicklin, Stuart A ^b   Fawcett, Lindsay ^e   Markwick, Rachel ^e   Charlton, Steven J ^e   Milligan, Graeme ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b Institute of Cardiovascular and Medical Sciences   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLEXANOX; ANTIASTHMATIC AGENT; ARGININE; BETA ARRESTIN 2; BUFROLIN; CHEMOKINE RECEPTOR; CROMOGLYCATE DISODIUM; DOXANTRAZOLE; G PROTEIN COUPLED RECEPTOR 35; LODOXAMIDE; NEDOCROMIL; NIVIMEDONE; PEMIROLAST; UNCLASSIFIED DRUG; ZAPRINAST;

ALLERGIC ASTHMA; ALLERGIC CONJUNCTIVITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL STRAIN HEK293; CELL STRAIN HT29; CONTROLLED STUDY; DRUG POTENCY; DRUG RECEPTOR BINDING; EMBRYO; GENETIC VARIABILITY; HUMAN; HUMAN CELL; LIGAND BINDING; MAST CELL; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MUTAGENESIS; MUTANT; NONHUMAN; ORTHOLOGY; PASSIVE SKIN ANAPHYLAXIS; PRIORITY JOURNAL; RAT; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84890673755     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.113.089482     Document Type: Article

References (31)

1. Abecasis GR, Altshuler D, Auton A, Brooks LD, Durbin RM, Gibbs RA, Hurles ME, and McVean GA; 1000 Genomes Project Consortium (2010) A map of human genome variation from population-scale sequencing. Nature 467:1061-1073 PubMed.
2. Ballesteros JA and Weinstein H (1995) Integrated methods for modeling G-protein coupled receptors. Methods Neurosci 366-428.
3. Cordomí A, Caltabiano G, and Pardo L (2012) Membrane protein simulations using AMBER force field and Berger lipid parameters. J Chem Theory Comput 8: 948-958.
4. Deng H, Hu H, He M, Hu J, Niu W, Ferrie AM, and Fang Y (2011) Discovery of 2-(4-methylfuran-2(5H)-ylidene)malononitrile and thieno[3,2-b]thiophene-2- carboxylic acid derivatives as G protein-coupled receptor 35 (GPR35) agonists. J Med Chem 54:7385-7396 PubMed.
5. Deng H, Hu H, Ling S, Ferrie AM, and Fang Y (2012) Discovery of natural phenols as G protein-coupled receptor-35 (GPR35) agonists. ACS Med Chem Lett 3:165-169.
6. Ellinghaus D, Folseraas T, Holm K, Ellinghaus E, Melum E, Balschun T, Laerdahl JK, Shiryaev A, Gotthardt DN, and Weismüller TJ et al. (2013) Genome-wide association analysis in Primary sclerosing cholangitis and ulcerative colitis identifies risk loci at GPR35 and TCF4. Hepatology 58:1074-1083 PubMed.
7. Funke M, Thimm D, Schiedel AC, and Müller CE (2013) 8-Benzamidochromen-4-one-2-carboxylic acids: Potent and selective agonists for the orphan G protein-coupled receptor GPR35. J Med Chem 56:5182-5197 PubMed.
8. Hess B, Kutzner C, van der Spoel D, and Lindahl E (2008) GROMACS 4: Algorithms for highly efficient, load-balanced, and scalable molecular simulation. J Chem Theory Comput 4:435-447.
9. Jenkins L, Alvarez-Curto E, Campbell K, de Munnik S, Canals M, Schlyer S, and Milligan G (2011) Agonist activation of the G protein-coupled receptor GPR35 involves transmembrane domain III and is transduced via Ga13 and b-arrestin-2. Br J Pharmacol 162:733-748 PubMed.
10. Jenkins L, Brea J, Smith NJ, Hudson BD, Reilly G, Bryant NJ, Castro M, Loza MI, and Milligan G (2010) Identification of novel species-selective agonists of the Gprotein-coupled receptor GPR35 that promote recruitment of b-arrestin-2 and activate Ga13. Biochem J 432:451-459 PubMed.
11. Jenkins L, Harries N, Lappin JE, MacKenzie AE, Neetoo-Isseljee Z, Souther C, McIver E, Nicklin SA, Taylor DL, and Milligan G (2012) Antagonists of GPR35 display high species ortholog selectivity and varying modes of action. J Pharmacol Exp Ther 343:683-695.
12. Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, Lee JC, Schumm LP, Sharma Y, and Anderson CA et al.; International IBD Genetics Consortium (IIBDGC) (2012) Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491:119-124 PubMed.
13. Liu C, Wu J, Zhu J, Kuei C, Yu J, Shelton J, Sutton SW, Li X, Yun SJ, and Mirzadegan T et al. (2009) Lactate inhibits lipolysis in fat cells through activation of an orphan G-protein-coupled receptor, GPR81. J Biol Chem 284: 2811-2822 PubMed.
14. Lumb EM, McHardy GJ, and Kay AB (1979) The orally administered anti-allergic agent, sodium nivimedone (BRL 10833); efficacy in bronchial asthma and effects on IgE, complement and eosinophils. Br J Clin Pharmacol 8:65-74 PubMed.
15. Mackenzie AE, Lappin JE, Taylor DL, Nicklin SA, and Milligan G (2011) GPR35 as a novel therapeutic target. Front Endocrinol (Lausanne) 2:68 PubMed.
16. Martí-Renom MA, Stuart AC, Fiser A, Sánchez R, Melo F, and Sali A (2000) Comparative protein structure modeling of genes and genomes. Annu Rev Biophys Biomol Struct 29:291-325 PubMed.
17. Mason JS, Bortolato A, Congreve M, and Marshall FH (2012) New insights from structural biology into the druggability of G protein-coupled receptors. Trends Pharmacol Sci 33:249-260 PubMed.
18. Milligan G (2011) Orthologue selectivity and ligand bias: Translating the pharmacology of GPR35. Trends Pharmacol Sci 32:317-325 PubMed.
19. Neetoo-Isseljee Z, MacKenzie AE, Southern C, Jerman J, McIver EG, Harries N, Taylor DL, and Milligan G (2013) High-throughput identification and characterization of novel, species-selective GPR35 agonists. J Pharmacol Exp Ther 344: 568-578 PubMed.
20. Oka S, Ota R, Shima M, Yamashita A, and Sugiura T (2010) GPR35 is a novel lysophosphatidic acid receptor. Biochem Biophys Res Commun 395:232-237 PubMed.
21. Okumura S, Baba H, Kumada T, Nanmoku K, Nakajima H, Nakane Y, Hioki K, and Ikenaka K (2004) Cloning of a G-protein-coupled receptor that shows an activity to transform NIH3T3 cells and is expressed in gastric cancer cells. Cancer Sci 95:131-135 PubMed.
22. Schröder R, Janssen N, Schmidt J, Kebig A, Merten N, Hennen S, Müller A, Blättermann S, Mohr-Andrä M, and Zahn S et al. (2010) Deconvolution of complex G protein-coupled receptor signaling in live cells using dynamic mass redistribution measurements. Nat Biotechnol 28:943-949 PubMed.
23. Schrödinger LLC (2012) The PyMOL Molecular Graphics System, version 1.5r3, Schrödinger LLC, Cambridge, MA.
24. Southern C, Cook JM, Neetoo-Isseljee Z, Taylor DL, Kettleborough CA,Merritt A, Bassoni DL, RaabWJ, Quinn E, andWehrman TS et al. (2013) Screening b-arrestin recruitment for the identification of natural ligands for orphan G-protein-coupled receptors. JBiomol Screen 18:599-609 PubMed.
25. Taniguchi Y, Tonai-Kachi H, and Shinjo K (2006) Zaprinast, a well-known cyclic guanosine monophosphate-specific phosphodiesterase inhibitor, is an agonist for GPR35. FEBS Lett 580:5003-5008 PubMed.
26. Venkatakrishnan AJ, Deupi X, Lebon G, Tate CG, Schertler GF, and Babu MM (2013) Molecular signatures of G-protein-coupled receptors. Nature 494:185-194 PubMed.
27. Wang J, Simonavicius N, Wu X, Swaminath G, Reagan J, Tian H, and Ling L (2006) Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. J Biol Chem 281:22021-22028 PubMed.
28. Wheatley M, Wootten D, Conner MT, Simms J, Kendrick R, Logan RT, Poyner DR, and Barwell J (2012) Lifting the lid on GPCRs: The role of extracellular loops. Br J Pharmacol 165:1688-1703 PubMed.
29. Yang Y, Lu JY, Wu X, Summer S, Whoriskey J, Saris C, and Reagan JD (2010) Gprotein-coupled receptor 35 is a target of the asthma drugs cromolyn disodium and nedocromil sodium. Pharmacology 86:1-5 PubMed.
30. Zhang C, Srinivasan Y, Arlow DH, Fung JJ, Palmer D, Zheng Y, Green HF, Pandey A, Dror RO, and Shaw DE et al. (2012) High-resolution crystal structure of human protease-activated receptor 1. Nature 492:387-392 PubMed.
31. Zhao P, Sharir H, Kapur A, Cowan A, Geller EB, Adler MW, Seltzman HH, Reggio PH, Heynen-Genel S, and Sauer M et al. (2010) Targeting of the orphan receptor GPR35 by pamoic acid: A potent activator of extracellular signal-regulated kinase and b-arrestin2 with antinociceptive activity. Mol Pharmacol 78:560-568 PubMed.